Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCRX logo BCRX
Upturn stock ratingUpturn stock rating
BCRX logo

BioCryst Pharmaceuticals Inc (BCRX)

Upturn stock ratingUpturn stock rating
$8.45
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $16.73

1 Year Target Price $16.73

Analysts Price Target For last 52 week
$16.73 Target price
52w Low $6.01
Current$8.45
52w High $11.31

Analysis of Past Performance

Type Stock
Historic Profit -22.12%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.77B USD
Price to earnings Ratio -
1Y Target Price 16.73
Price to earnings Ratio -
1Y Target Price 16.73
Volume (30-day avg) 12
Beta 1.1
52 Weeks Range 6.01 - 11.31
Updated Date 08/15/2025
52 Weeks Range 6.01 - 11.31
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.18

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-04
When -
Estimate 0.01
Actual 0.15

Profitability

Profit Margin -6.41%
Operating Margin (TTM) 18.23%

Management Effectiveness

Return on Assets (TTM) 7.46%
Return on Equity (TTM) -1925.37%

Valuation

Trailing PE -
Forward PE 129.87
Enterprise Value 2216965633
Price to Sales(TTM) 3.18
Enterprise Value 2216965633
Price to Sales(TTM) 3.18
Enterprise Value to Revenue 3.98
Enterprise Value to EBITDA 34.95
Shares Outstanding 209920000
Shares Floating 207688976
Shares Outstanding 209920000
Shares Floating 207688976
Percent Insiders 1.26
Percent Institutions 90.4

ai summary icon Upturn AI SWOT

BioCryst Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

BioCryst Pharmaceuticals, Inc. was founded in 1986. Initially focused on structure-guided drug design, it has evolved into a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel small molecule medicines that address unmet medical needs.

business area logo Core Business Areas

  • Hereditary Angioedema (HAE): BioCryst's primary focus is on developing and commercializing treatments for HAE, with ORLADEYO as its flagship product.
  • Complement Inhibition: The company is also developing other compounds targeting complement inhibition for various autoimmune and inflammatory diseases.

leadership logo Leadership and Structure

BioCryst is led by CEO Jon Stonehouse. The company has a typical biopharmaceutical organizational structure with departments focused on research and development, commercial operations, finance, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • ORLADEYO (berotralstat): ORLADEYO is an oral, once-daily treatment for the prevention of HAE attacks in adult and pediatric patients 12 years and older. Competitors include Takeda's TAKHZYRO and CSL Behring's HAEGARDA. Global net revenue for 2023 was approximately $325.0 million

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and strong competition. The market for HAE treatments is growing due to increased awareness and improved diagnosis rates.

Positioning

BioCryst is a key player in the HAE market with ORLADEYO, offering a convenient oral option compared to injectable treatments. Their competitive advantage lies in the oral administration and a targeted mechanism of action.

Total Addressable Market (TAM)

The total addressable market for HAE treatments is estimated to be in the billions of dollars annually. BioCryst is positioned to capture a significant share of this market with ORLADEYO and potential future products.

Upturn SWOT Analysis

Strengths

  • Oral HAE treatment (ORLADEYO)
  • Targeted drug design expertise
  • Growing revenue and market share
  • Strong intellectual property protection

Weaknesses

  • Reliance on a single product (ORLADEYO)
  • Competition from established players
  • High R&D expenses
  • Vulnerability to patent challenges

Opportunities

  • Expanding ORLADEYO to new markets
  • Developing new indications for ORLADEYO
  • Advancing pipeline programs targeting complement inhibition
  • Potential acquisitions or partnerships

Threats

  • Competition from new HAE treatments
  • Patent expiration of ORLADEYO
  • Regulatory hurdles
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • TAK (Takeda Pharmaceutical Company Limited), CSL (CSL Behring)
  • KALV (KalVista Pharmaceuticals)

Competitive Landscape

BioCryst competes with established pharmaceutical companies in the HAE market. ORLADEYO's oral administration provides a competitive advantage. Their pipeline programs represent future growth opportunities.

Growth Trajectory and Initiatives

Historical Growth: BioCryst has experienced significant revenue growth in recent years due to the commercial success of ORLADEYO.

Future Projections: Analyst estimates suggest continued revenue growth driven by ORLADEYO and potential pipeline advancements. Specific revenue projections are dependent on analyst forecasts.

Recent Initiatives: Recent initiatives include expanding ORLADEYO's availability globally and advancing clinical trials for new indications and pipeline programs.

Summary

BioCryst Pharmaceuticals is strongly positioned in the HAE market with Orladeyo, which drives revenue growth. However, its reliance on a single product makes it vulnerable. Expanding to new markets and advancing pipeline programs are crucial. Competition from established players is a key challenge to watch.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • BioCryst Pharmaceuticals Investor Relations Website
  • SEC Filings
  • Analyst Reports (FactSet, Bloomberg)
  • Company Press Releases

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share and competitor data are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioCryst Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 1994-03-03
CEO & Executive Director Mr. Jon P. Stonehouse
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 580
Full time employees 580

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.